Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
New Delhi, Dec 30 (PTI) Drug firm Zydus Cadila on Wednesday said it has received approval from the Drug Controller General of India (DCGI) for Saroglitazar Mg, used for the treatment of non-alcoholic fatty liver disease (NAFLD), in the nation. Zydus Cadila explained the prevalence of NAFLD in India is estimated to be nearly 25-30 percent of the overall population.
This NAFLD condition could progress to NASH, cirrhosis and liver failure.
It’s a large unmet medical need as there is currently no approved drug for the treatment of NAFLD and NASH anywhere in the world, Zydus Cadila said.
Pankaj Patel, the Chairman of Zydus Group, stated with Saroglitazar Mg, the company has managed to successfully provide an innovative medicine for dealing with chronic liver diseases like NAFLD and NASH and helping patients in leading healthier lives.
In March 2020, Saroglitazar Mg had received approval for the treatment of NASH. PTI SVK MR MR
